logo
Preface
Aromatase inhibitors and xenograft studies
Association between breast cancer subtypes and response to neoadjuvant anastrozole
Tissue-specific regulation of aromatase promoter II by the orphan nuclear receptor LRH-1 in breast adipose stromal fibroblasts
Molecular endocrinology and breast cancer – A reed before the wind lives on (a tribute to Professor Mike Reed)
Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors
Higher order organization of human placental aromatase
Aromatase in human lung carcinoma
Overview of adjuvant trials of aromatase inhibitors in early breast cancer
Promoter-specific effects of metformin on aromatase transcript expression
An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition
Predictive algorithms for adjuvant therapy: TransATAC
Pharmacology of arthralgia with estrogen deprivation
Recent data on intratumor estrogens in breast cancer
Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy
Mechanical phenotype is important for stromal aromatase expression
Binding features of steroidal and nonsteroidal inhibitors
The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer
Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women
Aromatase and its inhibition in behaviour, obsessive compulsive disorder and parkinsonism